Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel (Temsirolimus) and Avastin (Bevacizumab) Versus Sutent (Sunitinib) and Versus a Combination of Avastin (Bevacizumab) and Roferon (Interferon [IFN] Alpha-2a) in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma.

X
Trial Profile

Open Label, Randomized, Multicenter Phase II Study of a Combination of Torisel (Temsirolimus) and Avastin (Bevacizumab) Versus Sutent (Sunitinib) and Versus a Combination of Avastin (Bevacizumab) and Roferon (Interferon [IFN] Alpha-2a) in First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Temsirolimus (Primary) ; Interferon alpha-2a; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms TORAVA
  • Most Recent Events

    • 22 Mar 2018 Results assessing effect of angiogenic treatment on VE cadherin post translational modifications using patient data from SUVEGIL and TORAVA trials published in the British Journal of Cancer
    • 29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
    • 15 Sep 2015 Results (metabolomic fingerprint analysis) published in the British Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top